Initiating Aripiprazole Lauroxil
The Journal of Clinical Psychiatry · 2024
DOI: 10.4088/jcp.23m15132 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Clinical Psychiatry, 2024. Verfasst von Roger W Sommi und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, University of Missouri-Kansas City, Kansas City, Missouri. Hauptthemen laut MEDLINE: Aripiprazole, Antipsychotic Agents, Drug Administration Schedule. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Abstract (Originalsprache)
Objective
Aripiprazole lauroxil (AL), a long-acting injectable antipsychotic, has 2 initiation options: 1-day (AL NanoCrystal Dispersion [ALNCD] injection plus 30 mg oral aripiprazole on day 1 only) and 21-day (15 mg oral aripiprazole for 21 days). This post hoc analysis assessed the safety and tolerability of both initiation approaches.
Methods
We analyzed data from the first 4 weeks of 2 AL studies, one using the 1-day initiation regimen (conducted between November 2017 and March 2019) and the other using the 21-day initiation regimen (conducted between December 2011 and March 2014). Outcomes of interest during the matched 4-week period included the likelihood of adverse events (AEs), including those associated with discontinuation, rated as serious, or of special interest (injection site reactions [ISRs] and akathisia).
Results
The 1-day (n = 99) and 21-day (n = 415) initiation regimens had comparable rates of AEs (57.6% and 52.0%, respectively; most were mild), serious AEs (2.0% and 1.4%), and AEs leading to discontinuation (4.0% and 3.1%). The incidence of ISRs was 11.1% after the ALNCD injection (day 1) in the 1-day initiation regimen. ISR rates for the AL starting doses were 9.2% for the 1-day regimen (AL 1064 mg on day 8) and 3.9% for the 21-day regimen (AL 441 mg/882 mg on day 1). Rates of akathisia were 9.1% and 11.1% for the 1-day and 21-day regimens, respectively. One patient discontinued because of an ISR in the 21-day study, and 2 patients in the 21-day study discontinued because of akathisia. Mean changes from baseline in week 4 Positive and Negative Syndrome Scale total scores were -17.4 (1-day) and -19.5 (21-day).
Conclusions
Four-week safety and tolerability were similar following the initiation of AL with either the 1-day or 21-day regimen, supporting the utility of both initiation regimens. Engaging patients in discussions regarding options for initiating AL may help facilitate shared decision-making and personalization of treatment for patients with schizophrenia. Trial Registration: ClinicalTrials.gov identifiers: NCT03345979 and NCT01469039.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, University of Missouri-Kansas City, Kansas City, Missouri.
- Division of Pharmacotherapy, College of Pharmacy, The University of Texas at Austin, San Antonio, Texas.
- Renaissance School of Medicine at Stony Brook University, Stony Brook, New York.
- Alkermes, Inc, Waltham, Massachusetts.
- Corresponding Author: Sergey Yagoda, MD, PhD, Alkermes, Inc, 900 Winter St, Waltham, MA 02451 (Sergey.Yagoda@alkermes.com).
Zitieren
APA
Sommi, R. W., Saklad, S. R., Weiden, P. J., Still, D., Wang, M., & Yagoda, S. (2024). Initiating Aripiprazole Lauroxil. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.23m15132
Vancouver
Sommi RW, Saklad SR, Weiden PJ, Still D, Wang M, Yagoda S. Initiating Aripiprazole Lauroxil. The Journal of Clinical Psychiatry. 2024. doi:10.4088/jcp.23m15132
BibTeX
@article{Sommi2024,
author = {Sommi, Roger W and Saklad, Stephen R and Weiden, Peter J and Still, Daniel and Wang, Meihua and Yagoda, Sergey},
title = {Initiating Aripiprazole Lauroxil},
journal = {The Journal of Clinical Psychiatry},
year = {2024},
doi = {10.4088/jcp.23m15132}
}
EUVIMED